Direct-acting antiviral therapy is associated with a reduced risk of selected immune-mediated inflammatory diseases in chronic hepatitis C infection: A real-world cohort study
Yeong-Jang Lin, Chia-Chih Kuo, Chih-Cheng Lai, Hung-An Chen, Chao-Yu Chen · 2026
Read Direct-acting antiviral therapy is associated with a reduced risk of selected immune-mediated inflammatory diseases in chronic hepatitis C infection: A real-world cohort study by Yeong-Jang Lin, Chia-Chih Kuo, Chih-Cheng Lai, Hung-An Chen, Chao-Yu Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351973.txt.
Description
Yeong-Jang Lin and four colleagues ask whether curing hepatitis C also calms the immune system. Their 2026 cohort study uses a global health records network covering 2015 to 2024. Chronic hepatitis C stirs immune dysfunction and raises autoimmune disease risk. Modern direct-acting antivirals cure the infection at high rates. The long-term immune consequences were unclear. Treated and untreated patients were matched one-to-one on starting characteristics. Each group held over thirty-five thousand people.
Treatment came with measurably lower autoimmune risk. Rheumatoid arthritis risk fell by about a sixth. Autoimmune hepatitis risk fell by nearly half. A platelet-destroying immune condition also grew rarer. Control outcomes and sensitivity checks supported the pattern's robustness. Curing a virus is already its own reward. Evidence that cure also lowers later autoimmune disease strengthens the case for treating every hepatitis C patient early, not only those with advanced liver damage.
Catalog record
| CREATOR | Yeong-Jang Lin, Chia-Chih Kuo, Chih-Cheng Lai, Hung-An Chen, Chao-Yu Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37954 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |